MTOR and rheumatoid arthritis: Front‐line RA therapies including glucocorticoids and DMARDs such as methotrexate, leflunomide, and hydroxychloroquine modify metabolism, affecting the glycolytic and mTOR pathways, highlighting the great potential that targeting metabolites holds for the treatment of RA [90].